Jiangxi Fushine Pharmaceutical Co., Ltd.

SZSE:300497.SZ

10.05 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q42014 Q1
Revenue 294.461341.984340.431323.231430.794457.727397.918415.052401.062428.816402.333363.562290.136380.715395.13383.993292.558449.193367.209387.08374.607297.157295.203271.083270.488316.738305.124254.596229.05243.808230.696202.378197.747203.662159.901143.918159.654142.255133.916135.533114.328
Cost of Revenue 268.558322.559288.911296.882369.012416.52356.203351.022335.835359.621303.683267.466223.583250.285252.221266.466167.311241.917213.544213.998200.131165.454190.759186.191168.774189.294185.759161.121145.135149.04136.866116.599109.388121.44989.77582.827104.7793.15993.32899.7484.314
Gross Profit 25.90319.42551.5226.34961.78241.20741.71564.03165.22669.19598.6596.09566.553130.43142.909117.527125.247207.276153.665173.082174.476131.703104.44484.892101.714127.445119.36593.47583.91494.76893.83185.77988.35882.21370.12661.09254.88449.09740.58835.79230.014
Gross Profit Ratio 0.0880.0570.1510.0820.1430.090.1050.1540.1630.1610.2450.2640.2290.3430.3620.3060.4280.4610.4180.4470.4660.4430.3540.3130.3760.4020.3910.3670.3660.3890.4070.4240.4470.4040.4390.4240.3440.3450.3030.2640.263
Reseach & Development Expenses 20.14918.85315.87533.95123.86220.16219.47821.65220.28318.74116.77526.21617.4915.89518.9129.50816.01316.78814.21916.76218.69212.71911.2838.05418.86941.76610.14359.9568.9718.092030.901011.606018.33108.374003.464
General & Administrative Expenses 79.363-14.0329.328-56.04279.172-8.88732.622-69.44789.269-13.7636.691-51.72872.947-11.64327.103-40.76922.797-10.28526.642-41.121.761-6.65721.307-41.65522.668-16.61229.329-59.99627.335-6.73627.22-55.00132.634-8.95720.461-29.08816.13-6.65712.892-27.3710.683
Selling & Marketing Expenses 7.0955.542.3566.1629.57310.6178.9888.7911.7825.9167.72412.7099.0824.9447.7645.1155.755.124.85610.4985.6297.493.8696.3036.8127.9174.2677.0293.1155.2972.8414.9024.5175.2743.6284.473.694.6612.6724.9252.763
SG&A 86.459-8.4931.684-49.8888.7451.7341.611-60.657101.051-7.84444.414-39.01882.029-6.69934.867-35.65428.548-5.16531.498-30.60327.390.83325.175-35.35229.479-8.69533.596-52.96830.45-1.43930.061-50.09937.151-3.68324.09-24.61719.82-1.99615.564-22.44513.447
Other Expenses -48.5560.121-0.274-3.1241.283-2.1630.223-86.5590.825-1.53-0.27-84.814-0.453-0.502-0.216-0.305-0.936-2.73-4.21-17.293-0.592-3.2810.259-4.012-0.9530.1310.75-3.1432.0024.689-0.084.4372.55610.3162.183.966-2.2010.3981.387-0.7541.481
Operating Expenses 58.05335.38740.356100.42671.49667.72163.35567.85367.43262.24161.88478.68362.82537.34550.91667.06925.0132.67945.53935.84249.80951.04437.238.34751.40951.75336.42152.11832.86337.62831.83345.96438.58631.56925.47426.60220.1321.59915.86820.23113.602
Operating Income -41.461-25.4724.102-143.322-18.179-34.086-33.802-178.753-0.17416.39628.576-123.6193.62588.19988.79924.30390.145167.405105.14113.809123.8777.69753.88829.52548.64681.2871.70941.97443.69152.88759.03346.82449.87750.05541.78730.5931.17426.00322.13612.22613.791
Operating Income Ratio -0.141-0.0740.012-0.443-0.042-0.074-0.085-0.431-00.0380.071-0.340.0120.2320.2250.0630.3080.3730.2860.2940.3310.2610.1830.1090.180.2570.2350.1650.1910.2170.2560.2310.2520.2460.2610.2130.1950.1830.1650.090.121
Total Other Income Expenses Net -0.1870.121-0.274-3.124-0.644-0.2370.223-7.778-0.008-0.697-0.27-0.765-0.453-0.502-0.216-0.305-0.936-2.73-4.21-17.293-0.592-3.2810.259-4.012-0.9530.1310.75-2.1571.2594.588-0.2221.2622.3619.3292.1352.909-2.35-0.2061.33-0.9691.481
Income Before Tax -41.648-25.3513.828-146.446-18.823-34.323-33.58-186.53-0.18115.69828.306-124.3843.17287.69788.58323.99889.208164.675100.9396.517123.27874.41764.14725.51347.69381.41172.45939.81744.9557.47558.81248.08652.23859.38443.92233.49828.82425.79723.46611.25815.272
Income Before Tax Ratio -0.141-0.0740.011-0.453-0.044-0.075-0.084-0.449-00.0370.07-0.3420.0110.230.2240.0620.3050.3670.2750.2490.3290.250.2170.0940.1760.2570.2370.1560.1960.2360.2550.2380.2640.2920.2750.2330.1810.1810.1750.0830.134
Income Tax Expense 0.5360.9324.568-16.0996.1470.0250.0115.2354.7136.4955.024-7.127-1.82710.06514.419-0.91614.09826.63316.8189.24920.2911.40410.5356.4476.47610.98810.8033.2267.487.6418.2286.9597.2649.8417.0464.255.2344.6533.8461.3682.281
Net Income -39.616-23.9281.468-119.163-21.962-29.528-30.147-187.3720.58817.36327.951-112.2448.70478.06274.30925.73674.306135.44983.80989.804101.83660.77153.42422.02740.69570.21561.78838.10138.33850.36250.7542.21145.2849.54336.87629.24823.5921.14419.629.88912.992
Net Income Ratio -0.135-0.070.004-0.369-0.051-0.065-0.076-0.4510.0010.040.069-0.3090.030.2050.1880.0670.2540.3020.2280.2320.2720.2050.1810.0810.150.2220.2030.150.1670.2070.220.2090.2290.2430.2310.2030.1480.1490.1470.0730.114
EPS -0.074-0.0440.003-0.22-0.041-0.055-0.056-0.350.0010.0330.052-0.20.020.140.140.0550.160.290.310.20.230.160.130.0510.110.170.150.0890.0940.120.120.110.110.120.0890.0970.0760.0680.06300.042
EPS Diluted -0.074-0.0440.003-0.22-0.041-0.055-0.056-0.350.0010.0330.05-0.20.020.140.140.0550.160.290.290.190.220.130.130.050.110.160.150.0890.0890.120.120.0990.110.120.0890.0970.0760.0680.06300.042
EBITDA -31.797-12.91315.079-88.709-7.428-18.21-21.394-92.15512.68927.51439.74-111.8657.79191.4795.77331.64792.34173.863108.173117.334130.73283.21772.40148.69553.04779.42386.26742.51752.47562.33861.89468.75149.01366.35645.12547.0843.72437.88132.26825.66322.345
EBITDA Ratio -0.108-0.0380.044-0.274-0.017-0.04-0.054-0.2220.0320.0640.099-0.3080.0270.240.2420.0820.3160.3870.2950.3030.3490.280.2450.180.1960.2510.2830.1670.2290.2560.2680.340.2480.3260.2820.3270.2740.2660.2410.1890.195